BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

486 related articles for article (PubMed ID: 25505128)

  • 1. Retinal toxicity, in vivo and in vitro, associated with inhibition of nicotinamide phosphoribosyltransferase.
    Zabka TS; Singh J; Dhawan P; Liederer BM; Oeh J; Kauss MA; Xiao Y; Zak M; Lin T; McCray B; La N; Nguyen T; Beyer J; Farman C; Uppal H; Dragovich PS; O'Brien T; Sampath D; Misner DL
    Toxicol Sci; 2015 Mar; 144(1):163-72. PubMed ID: 25505128
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cardiotoxicity Associated with Nicotinamide Phosphoribosyltransferase Inhibitors in Rodents and in Rat and Human-Derived Cells Lines.
    Misner DL; Kauss MA; Singh J; Uppal H; Bruening-Wright A; Liederer BM; Lin T; McCray B; La N; Nguyen T; Sampath D; Dragovich PS; O'Brien T; Zabka TS
    Cardiovasc Toxicol; 2017 Jul; 17(3):307-318. PubMed ID: 27783203
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preclinical models of nicotinamide phosphoribosyltransferase inhibitor-mediated hematotoxicity and mitigation by co-treatment with nicotinic acid.
    Tarrant JM; Dhawan P; Singh J; Zabka TS; Clarke E; DosSantos G; Dragovich PS; Sampath D; Lin T; McCray B; La N; Nguyen T; Kauss A; Dambach D; Misner DL; Diaz D; Uppal H
    Toxicol Mech Methods; 2015 Mar; 25(3):201-11. PubMed ID: 25894564
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Supplementation of nicotinic acid with NAMPT inhibitors results in loss of in vivo efficacy in NAPRT1-deficient tumor models.
    O'Brien T; Oeh J; Xiao Y; Liang X; Vanderbilt A; Qin A; Yang L; Lee LB; Ly J; Cosino E; LaCap JA; Ogasawara A; Williams S; Nannini M; Liederer BM; Jackson P; Dragovich PS; Sampath D
    Neoplasia; 2013 Dec; 15(12):1314-29. PubMed ID: 24403854
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of amides derived from 1H-pyrazolo[3,4-b]pyridine-5-carboxylic acid as potent inhibitors of human nicotinamide phosphoribosyltransferase (NAMPT).
    Zheng X; Bair KW; Bauer P; Baumeister T; Bowman KK; Buckmelter AJ; Caligiuri M; Clodfelter KH; Feng Y; Han B; Ho YC; Kley N; Li H; Liang X; Liederer BM; Lin J; Ly J; O'Brien T; Oeh J; Oh A; Reynolds DJ; Sampath D; Sharma G; Skelton N; Smith CC; Tremayne J; Wang L; Wang W; Wang Z; Wu H; Wu J; Xiao Y; Yang G; Yuen PW; Zak M; Dragovich PS
    Bioorg Med Chem Lett; 2013 Oct; 23(20):5488-97. PubMed ID: 24021463
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Loss of NAPRT1 expression by tumor-specific promoter methylation provides a novel predictive biomarker for NAMPT inhibitors.
    Shames DS; Elkins K; Walter K; Holcomb T; Du P; Mohl D; Xiao Y; Pham T; Haverty PM; Liederer B; Liang X; Yauch RL; O'Brien T; Bourgon R; Koeppen H; Belmont LD
    Clin Cancer Res; 2013 Dec; 19(24):6912-23. PubMed ID: 24097869
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of a Highly Selective NAMPT Inhibitor That Demonstrates Robust Efficacy and Improved Retinal Toxicity with Nicotinic Acid Coadministration.
    Zhao G; Green CF; Hui YH; Prieto L; Shepard R; Dong S; Wang T; Tan B; Gong X; Kays L; Johnson RL; Wu W; Bhattachar S; Del Prado M; Gillig JR; Fernandez MC; Roth KD; Buchanan S; Kuo MS; Geeganage S; Burkholder TP
    Mol Cancer Ther; 2017 Dec; 16(12):2677-2688. PubMed ID: 29054982
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression patterns of nicotinamide phosphoribosyltransferase and nicotinic acid phosphoribosyltransferase in human malignant lymphomas.
    Olesen UH; Hastrup N; Sehested M
    APMIS; 2011 Apr; 119(4-5):296-303. PubMed ID: 21492230
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structural and biochemical analyses of the catalysis and potency impact of inhibitor phosphoribosylation by human nicotinamide phosphoribosyltransferase.
    Oh A; Ho YC; Zak M; Liu Y; Chen X; Yuen PW; Zheng X; Liu Y; Dragovich PS; Wang W
    Chembiochem; 2014 May; 15(8):1121-30. PubMed ID: 24797455
    [TBL] [Abstract][Full Text] [Related]  

  • 10. From the Cover: Inhibitors of Nicotinamide Phosphoribosyltransferase Cause Retinal Damage in Larval Zebrafish.
    Cassar S; Dunn C; Olson A; Buck W; Fossey S; Ramos MF; Sancheti P; Stolarik D; Britton H; Cole T; Bratcher N; Huang X; Peterson R; Longenecker K; LeRoy B
    Toxicol Sci; 2018 Feb; 161(2):300-309. PubMed ID: 29378070
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oleate ameliorates palmitate-induced reduction of NAMPT activity and NAD levels in primary human hepatocytes and hepatocarcinoma cells.
    Penke M; Schuster S; Gorski T; Gebhardt R; Kiess W; Garten A
    Lipids Health Dis; 2017 Oct; 16(1):191. PubMed ID: 28974242
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of novel resistance mechanisms to NAMPT inhibition via the de novo NAD
    Guo J; Lam LT; Longenecker KL; Bui MH; Idler KB; Glaser KB; Wilsbacher JL; Tse C; Pappano WN; Huang TH
    Biochem Biophys Res Commun; 2017 Sep; 491(3):681-686. PubMed ID: 28756225
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of nicotinamide phosphoribosyltransferase (NAMPT) as a therapeutic strategy in cancer.
    Sampath D; Zabka TS; Misner DL; O'Brien T; Dragovich PS
    Pharmacol Ther; 2015 Jul; 151():16-31. PubMed ID: 25709099
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enzymes in the NAD+ salvage pathway regulate SIRT1 activity at target gene promoters.
    Zhang T; Berrocal JG; Frizzell KM; Gamble MJ; DuMond ME; Krishnakumar R; Yang T; Sauve AA; Kraus WL
    J Biol Chem; 2009 Jul; 284(30):20408-17. PubMed ID: 19478080
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nicotinamide phosphoribosyltransferase (Nampt) in carcinogenesis: new clinical opportunities.
    Chen H; Wang S; Zhang H; Nice EC; Huang C
    Expert Rev Anticancer Ther; 2016 Aug; 16(8):827-38. PubMed ID: 27186719
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nicotinamide phosphoribosyltransferase promotes epithelial-to-mesenchymal transition as a soluble factor independent of its enzymatic activity.
    Soncini D; Caffa I; Zoppoli G; Cea M; Cagnetta A; Passalacqua M; Mastracci L; Boero S; Montecucco F; Sociali G; Lasigliè D; Damonte P; Grozio A; Mannino E; Poggi A; D'Agostino VG; Monacelli F; Provenzani A; Odetti P; Ballestrero A; Bruzzone S; Nencioni A
    J Biol Chem; 2014 Dec; 289(49):34189-204. PubMed ID: 25331943
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Loss of NAMPT in aging retinal pigment epithelium reduces NAD
    Jadeja RN; Powell FL; Jones MA; Fuller J; Joseph E; Thounaojam MC; Bartoli M; Martin PM
    Aging (Albany NY); 2018 Jun; 10(6):1306-1323. PubMed ID: 29905535
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery of potent and efficacious cyanoguanidine-containing nicotinamide phosphoribosyltransferase (Nampt) inhibitors.
    Zheng X; Baumeister T; Buckmelter AJ; Caligiuri M; Clodfelter KH; Han B; Ho YC; Kley N; Lin J; Reynolds DJ; Sharma G; Smith CC; Wang Z; Dragovich PS; Oh A; Wang W; Zak M; Wang Y; Yuen PW; Bair KW
    Bioorg Med Chem Lett; 2014 Jan; 24(1):337-43. PubMed ID: 24279990
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nicotinic Acid Phosphoribosyltransferase Regulates Cancer Cell Metabolism, Susceptibility to NAMPT Inhibitors, and DNA Repair.
    Piacente F; Caffa I; Ravera S; Sociali G; Passalacqua M; Vellone VG; Becherini P; Reverberi D; Monacelli F; Ballestrero A; Odetti P; Cagnetta A; Cea M; Nahimana A; Duchosal M; Bruzzone S; Nencioni A
    Cancer Res; 2017 Jul; 77(14):3857-3869. PubMed ID: 28507103
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A fluorometric assay for high-throughput screening targeting nicotinamide phosphoribosyltransferase.
    Zhang RY; Qin Y; Lv XQ; Wang P; Xu TY; Zhang L; Miao CY
    Anal Biochem; 2011 May; 412(1):18-25. PubMed ID: 21211508
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.